Abstract
Foretinib exhibits superior efficacy to approved drugs in AML with FLT3-ITD mutations and retains activity in AML with secondary FLT3 mutations that mediate resistance to clinical FLT3 inhibitors.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have